Epigenetic enzymes control the mechanics of genetic expression, acting as "on" and "off" switches for the human genome. Malfunctions of these enzymes are implicated in a number of cancer, immunological, and neurodegenerative conditions. Understanding these mechanisms can explain why one person with a genetic disposition to a certain type of cancer may become sick while another with the same genetic marker may stay healthy.
The project will consist of taking a library of 1400 compounds, including almost every
Dr. Haiching Ma, Chief Science Officer of RBC and Principal Investigator of the study, said, "This project will represent the first systematic look at how current pharmaceuticals affect epigenetic function. The potential exists for some exciting developments as a result. We're very pleased that NCATS saw the same potential in this project as we did."
Most Popular Stories
- Study: Recessions Can Postpone Motherhood Forever
- Hispanic Entrepreneurs Short-changed in Texas
- Tim Cook Has Proved That Apple is His Baby
- China Approves iPhone 6 After Security Assurances
- Who Is Daniel Ivascyn?
- U.S. Home Prices Rose at Slowest Pace in 20 Months
- Hispanics Carry Big Clout: Census
- Netflix Eyes Hollywood With Feature Film
- Washington's 'The Equalizer' Debuts With $35 Million
- Meet the YouTube Tech Review Sensation